Executive Summary of the 2021 International Conference of Korean Dementia Association: A Report From the Academic Committee of the Korean Dementia Association
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Recently, aducanumab, a beta amyloid targeted immunotherapy, has been approved by the US Food and Drug Administration for the treatment of Alzheimer’s dementia (AD). Although many questions need to be answered, this approval provides a promising hope for the development of AD drugs that could be supported by new biomarkers such as blood-based ones and composite neuropsychological tests that can confirm pathologic changes in early stages of AD. It is important to elucidate the complexity of AD which is known to be associated with other factors such as vascular etiologies and neuro-inflammation. Through the second international conference of the Korean Dementia Association (KDA), researchers from all over the world have participated in the exchange of opinions with KDA members on the most up-to-date topics. The Academic Committee of the KDA summarizes lectures to provide the depth of the conference as well as discussions. This will be an important milestone to widen the latest knowledge in the research of AD’s diagnosis, therapeutics, pathogenesis that can lead to the establishment of future directions.
Abstract
Recently, aducanumab, a beta amyloid targeted immunotherapy, has been approved by the US Food and Drug Administration for the treatment of Alzheimer’s dementia (AD). Although many questions need to be answered, this approval provides a promising hope for the development of AD drugs that could be supported by new biomarkers such as blood-based ones and composite neuropsychological tests that can confirm pathologic changes in early stages of AD. It is important to elucidate the complexity of AD which is known to be associated with other factors such as vascular etiologies and neuro-inflammation. Through the second international conference of the Korean Dementia Association (KDA), researchers from all over the world have participated in the exchange of opinions with KDA members on the most up-to-date topics. The Academic Committee of the KDA summarizes lectures to provide the depth of the conference as well as discussions. This will be an important milestone to widen the latest knowledge in the research of AD’s diagnosis, therapeutics, pathogenesis that can lead to the establishment of future directions.
참고문헌 (30)
- Gurdon B, "Pursuit of precision medicine : Systems biology approaches in Alzheimer’s disease mouse models", Neurobiol Dis, 161, pp.105558~ (2021)
- Kim HR, "Genetic variants beyond amyloid and tau associated with cognitive decline: a cohort study", Neurology, 95, pp.e2366~e2377 (2020)
- Cummings J, "Alzheimer’s disease drug development pipeline: 2021", Alzheimers Dement (N Y), 7, pp.e12179~ (2021)
- Tariot PN, "Trial of pimavanserin in dementia-related psychosis", N Engl J Med, 385, pp.309~319 (2021)
- Sevigny J, "The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease", Nature, 537, pp.50~56 (2016)
- Cummings J, "Aducanumab produced a clinically meaningful benefit in association with amyloid lowering", Alzheimers Res Ther, 13, pp.98~ (2021)
- Haeberlein SB, "EMERGE and ENGAGE topline results : two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s disease", 12th Clinical Trials on Alzheimer's Disease, pp.1~25 (2019)
- Li C, "Tau-based therapies in neurodegeneration : opportunities and challenges", Nat Rev Drug Discov, 16, pp.863~883 (2017)
- Iadecola C, "Neurovascular and cognitive dysfunction in hypertension", Circ Res, 124, pp.1025~1044 (2019)
- Jacobson AM, "Cognitive performance declines in older adults with type 1 diabetes : results from 32 years of follow-up in the DCCT and EDIC Study", Lancet Diabetes Endocrinol, 9, pp.436~445 (2021)
- Koekkoek PS, "Cognitive function in patients with diabetes mellitus : guidance for daily care", Lancet Neurol, 14, pp.329~340 (2015)
- Xue M, "Diabetes mellitus and risks of cognitive impairment and dementia : a systematic review and meta-analysis of 144 prospective studies", Ageing Res Rev, 55, pp.100944~ (2019)
- Biessels GJ, "Risk of dementia in diabetes mellitus : a systematic review", Lancet Neurol, 5, pp.64~74 (2006)
- Janssen J, "HbA1c, insulin resistance, and β-cell function in relation to cognitive function in type 2 diabetes : the CAROLINA cognition substudy", Diabetes Care, 42, pp.e1~e3 (2019)
- Biessels GJ, "Cognitive decline and dementia in diabetes mellitus : mechanisms and clinical implications", Nat Rev Endocrinol, 14, pp.591~604 (2018)
- Duering M, "Strategic role of frontal white matter tracts in vascular cognitive impairment : a voxel-based lesion-symptom mapping study in CADASIL", Brain, 134, pp.2366~2375 (2011)
- Duering M, "Strategic white matter tracts for processing speed deficits in age-related small vessel disease", Neurology, 82, pp.1946~1950 (2014)
- Duering M, "Acute infarcts cause focal thinning in remote cortex via degeneration of connecting fiber tracts", Neurology, 84, pp.1685~1692 (2015)
- Duering M, "Remote changes after ischaemic infarcts : a distant target for therapy", Brain, 140, pp.1818~1820 (2017)
- Tiedt S, "Serum neurofilament light : a biomarker of neuroaxonal injury after ischemic stroke", Neurology, 91, pp.e1338~e1347 (2018)
- Wollenweber FA, "Prevalence of amyloid positron emission tomographic positivity in poststroke mild cognitive impairment", Stroke, 47, pp.2645~2648 (2016)
- Mok VCT, "Delayed-onset dementia after stroke or transient ischemic attack", Alzheimers Dement, 12, pp.1167~1176 (2016)
- Zietemann V, "Early MoCA predicts long-term cognitive and functional outcome and mortality after stroke", Neurology, 91, pp.e1838~e1850 (2018)
- Schindler SE, "High-precision plasma β-amyloid 42", 40 predicts current and future brain amyloidosis, 2019, pp.93, e1647~e1659
- Janelidze S, "Head-to-head comparison of 8 plasma amyloid-β 42", 40 assays in Alzheimer disease, 2021, pp.78, 1375~1382
- Barthélemy NR, "Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease", J Exp Med, 217, pp.e20200861~ (2020)
- Horie K, "CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease", Brain, 144, pp.515~527 (2021)
- "Seventy-first Regional Committee for Europe: virtual session, 13–15 September 2021: global actions on epilepsy and other neurological disorders" (2021)[URL]
- Livingston G, "Dementia prevention, intervention, and care", Lancet, 390, pp.2673~2734 (2017)
- "Dementia, disability and frailty in later life – midlife approaches to delay or prevent onset" (2015)[URL]